Paratek Pharmaceuticals (Paratek Pharmaceuticals) Total Inventories : $11.4 Mil (As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals Total Inventories?

Paratek Pharmaceuticals's total inventories for the quarter that ended in Jun. 2023 was $11.4 Mil. Paratek Pharmaceuticals's average total inventories from the quarter that ended in Mar. 2023 to the quarter that ended in Jun. 2023 was $12.7 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Paratek Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was $-4.66.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Paratek Pharmaceuticals's Days Inventory for the three months ended in Jun. 2023 was 265.33.

Inventory Turnover measures how fast the company turns over its inventory within a year. Paratek Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2023 was 0.34.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Paratek Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.33.

Paratek Pharmaceuticals Total Inventories Historical Data

The historical data trend for Paratek Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Total Inventories Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Inventories

Get a 7-Day Free Trial

0.60

11.58

14.56

11.02

16.57

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Inventories	Get a 7-Day Free Trial															13.08	20.75	16.57	13.99	11.41

Paratek Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Paratek Pharmaceuticals (NAS:PRTK) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Paratek Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is

	Net-Net Working Capital Per Share (Q: Jun. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(42.685	+	0.75 * 42.291	+	0.5 * 11.413	-	347.157
-	0	-	0)	/	57.2822
=	-4.66

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Paratek Pharmaceuticals's Days Inventory for the three months ended in Jun. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2023 )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
	=	12.701	/	4.368	*	365 / 4
	=	265.33

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Paratek Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2023 )	/	Average Total Inventories (Q: Jun. 2023 )
	=	4.368	/	12.701
	=	0.34

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Paratek Pharmaceuticals's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	12.701	/	38.062
	=	0.33

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Paratek Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Executives

Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz	director	C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh	director, officer: CEO	75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel	officer: CLO, General Counsel & Sec.	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow	officer: President & Chief Commercial	C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner	officer: Chief Development & Regulatory	C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie	director	101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann	director	LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham	director, officer: Exec. Chairman of the Board	890 WINTER STREET, WALTHAM MA 02451
James D Dondero	10 percent owner	300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan	officer: Chief Financial Officer	75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199